Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis
The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Objectives The objective of this study was to evaluate the efficacy and safety of atomoxetine in children and adolescents. Materials and methods We searched for studies published between 1985 and 2006 through Medline, PubMed, PsychInfo and Cochrane Central Register of Controlled Trials (CENTRAL 2006 Issue 3) using keywords related to atomoxetine and attention-deficit/hyperactivity disorder (ADHD) and scanned though reference lists. We included nine randomized placebo-controlled trials (atomoxetine:placebo = 1,150:678). Results Atomoxetine was superior (p Conclusions Atomoxetine is efficacious in reducing ADHD symptoms. It may have a role in treating comorbid ODD or depression, and probably in comorbid anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis of seven studies with over 1,600 participants reported that atomoxetine moderately reduced ADHD symptoms.”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Cheng et al., 2007
In the citing paper
“Among nonstimulant medications, 1 selective norepinephrine reuptake inhibitor, atomoxetine,99,100 and 2 selective α-2 adrenergic agonists, extended-release guanfacine101,102 and extended-release clonidine,103 have also demonstrated efficacy in reducing core symptoms among school-aged children and adolescents”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [99]
In the citing paper
“Efficacy of both methylphenidate and atomoxetine has been established in placebo controlled trials [12-15].”
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
(1998) · Cited by 2,026
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · cited 2×
“Oppositional defiant disorder (ODD) is the most common comorbid condition in ADHD, and it affects 30–60% of children with ADHD (Biederman et al. 1991; Goldman et al. 1998; Jensen et al. 2001).”
BackgroundConners' rating scales-revised : technical manual
Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,368
Johnston, C., & Mash, E. J. (2001) · Clinical Child and Family Psychology Review · doi:10.1023/a:1017592030434 · Cited by 1,161 · cited 2×
“2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al.”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 3×
“Atomoxetine has a theoretical advantage over methylphenidate because its action spares the striatum and nucleus accumbens (Bymaster et al. 2002) that are affected in substance abuse, particularly in comorbid ODD patients who are at risk of substance abuse (Wilens et al. 2006).”
BackgroundGender Differences in ADHD: A Meta-Analysis and Critical Review
GAUB, M., & CARLSON, C. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199708000-00011 · Cited by 1,117 · cited 1×
“The former explanation may be further explained by the relatively less severe externalizing or disruptive behaviours in girls (Biederman et al. 2002; Gaub and Carlson 1997), which upon drug treatment may appear to improve more than boys in the eyes of the instrument raters.”
BackgroundDiagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
ADHD Comorbidity Findings From the MTA Study: Comparing Comorbid Subgroups
JENSEN, P. S., HINSHAW, S. P., KRAEMER, H. C., LENORA, N., NEWCORN, J. H., ABIKOFF, H. B., MARCH, J. S., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00009 · Cited by 974 · cited 1×
“Oppositional defiant disorder (ODD) is the most common comorbid condition in ADHD, and it affects 30–60% of children with ADHD (Biederman et al. 1991; Goldman et al. 1998; Jensen et al. 2001).”
BackgroundGender Differences in ADHD: A Meta-Analysis and Critical Review
GAUB, M., & CARLSON, C. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199708000-00023 · Cited by 870
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796 · cited 2×
“…to the NNT of 3.8 (±0.21) reported by Banaschewski et al. (2006), and they compare favourably to the NNTs required for the treatment of adult depression (NNT=0.5; Geddes and Butler 2002), obsessive–compulsive disorder (NNT=9; Soomro 2002) and schizophrenia (NNT=0.25 to 20; Leucht et al. 1999).”
BackgroundInfluentialAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · cited 2×
“Sixteen articles were clinical trials that used atomoxetine to treat ADHD patients, two studies of which were conducted in adults (Spencer et al. 1998; Michelson et al. 2003), two studies did not have placebo control groups (Kratochvil et al.”
BackgroundResultMichelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666 · cited 7×
“CHQ: Buitelaar et al. (2006), Michelson et al. (2001) and Michelson et al. (2004).”
BackgroundInfluential(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1088 · Cited by 652
BAGWELL, C. L., MOLINA, B. S. G., PELHAM, W. E., & HOZA, B. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200111000-00008 · Cited by 627 · cited 2×
“2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al. 2001; Greene et al. 2001; Maedgen and Carlson 2000), and improvement in quality of life (QoL) is a desirable quality of any ADHD treatment.”
BackgroundMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 6×
“…Placebo NNT (95% CI) Buitelaar et al. 2006 2/81 10/82 10.28 (5.69, 53.24) Kelsey et al. 2004 67/107 15/45 3.40 (2.18, 7.85) Michelson et al. 2001 – – – – Michelson et al. 2002 50/84 26/83 3.54 (2.34, 7.29) Michelson et al. 2004 65/292 47/124 6.39 (3.93, 17.06) Spencer et al. 2002; Study 1 41/64…”
BackgroundInfluentialKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 19×
“Six subject characteristics were found to be significant: men (regression coefficient −0.01; p=0.02), ADHD hyperactive/impulsive subtype (regression coefficient −0.09; p=0.01), oppositional defiant disorder (regression coefficient −0.02; p=0.01), baseline ADHD-RS-IV total score (regression coefficient 0.01; p= 0.02),…”
BackgroundInfluentialSocial Functioning and Emotional Regulation in the Attention Deficit Hyperactivity Disorder Subtypes
Wheeler Maedgen, J., & Carlson, C. L. (2000) · Journal of Clinical Child Psychology · doi:10.1207/s15374424jccp2901_4 · Cited by 462 · cited 2×
“2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al. 2001; Greene et al. 2001; Maedgen and Carlson 2000), and improvement in quality of life (QoL) is a desirable quality of any ADHD treatment.”
BackgroundComorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.
Pliszka, S. R. (1998) · The Journal of Clinical Psychiatry · Cited by 433
Jensen, P. N., Arnold, L. E., Richters, J., Severe, J. B., Vereen, D. R., Vitiello, B., Schiller, E., Hinshaw, S. P., Elliott, G. R., Conners, C., et al. (1999) · Institutional Research Information System University of Turin (University of Turin) · Cited by 432
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375
Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Wilens, T., Prince, J., Hatch, M., Jones, J., Harding, M., Faraone, S. V., & Seidman, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.693 · Cited by 335 · cited 2×
“Sixteen articles were clinical trials that used atomoxetine to treat ADHD patients, two studies of which were conducted in adults (Spencer et al. 1998; Michelson et al. 2003), two studies did not have placebo control groups (Kratochvil et al.”
BackgroundSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 13×
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundMethodInfluentialMICHELSON, D., BUITELAAR, J. K., DANCKAERTS, M., GILLBERG, C., SPENCER, T. J., ZUDDAS, A., FARIES, D. E., ZHANG, S., & BIEDERMAN, J. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000125089.35109.81 · Cited by 307 · cited 8×
“CHQ: Buitelaar et al. (2006), Michelson et al. (2001) and Michelson et al. (2004).”
BackgroundInfluentialTANNOCK, R., ICKOWICZ, A., & SCHACHAR, R. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199507000-00012 · Cited by 305 · cited 6×
“1995) with methylphenidate treatment, although other studies found methylphenidate to be useful (Livingstone et al. 1990; Tannock et al. 1995), and others found no differential response in either comorbid status (Diamond et al.”
BackgroundResultInfluentialEffect of Anxiety on Cognition, Behavior, and Stimulant Response in ADHD
PLISZKA, S. R. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198911000-00012 · Cited by 293 · cited 2×
“Children with comorbid ADHD and anxiety are reported to experience less behavioural response (Taylor et al. 1987; Pliszka 1989), develop tics and dysphoric symptoms (Tannock and Schachar 1992), and have less improvements in working memory (Tannock et al.”
BackgroundSwanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216 · cited 2×
“Methylphenidate also appears to have acute tolerance (Swanson et al. 1999), and an optimum dosing regimen (e.g. frequency of doses) has to take this into account.”
BackgroundTaylor, E., Schachar, R., Thorley, G., Wieselberg, H. M., Everitt, B., & Rutter, M. (1987) · Psychological Medicine · doi:10.1017/s0033291700013039 · Cited by 210 · cited 1×
“Children with comorbid ADHD and anxiety are reported to experience less behavioural response (Taylor et al. 1987; Pliszka 1989), develop tics and dysphoric symptoms (Tannock and Schachar 1992), and have less improvements in working memory (Tannock et al. 1995) with methylphenidate treatment,…”
BackgroundSocial Impairment in Girls With ADHD: Patterns, Gender Comparisons, and Correlates
GREENE, R. W., BIEDERMAN, J., FARAONE, S. V., MONUTEAUX, M. C., MICK, E., DuPRE, E. P., FINE, C. S., & GORING, J. C. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200106000-00016 · Cited by 206 · cited 2×
“2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al. 2001; Greene et al. 2001; Maedgen and Carlson 2000), and improvement in quality of life (QoL) is a desirable quality of any ADHD treatment.”
BackgroundNewcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200503000-00008 · Cited by 174 · cited 10×
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundResultInfluentialLeonard, H. L., Ale, C. M., Freeman, J. B., Garcia, A. M., & Ng, J. S. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.06.002 · Cited by 172
Kratochvil, C. J., Newcorn, J. H., Arnold, L. E., Duesenberg, D., Emslie, G. J., Quintana, H., Sarkis, E. H., Wagner, K. D., Gao, H., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000169012.81536.38 · Cited by 152 · cited 6×
“Addition of fluoxetine to atomoxetine (compared to atomoxetine alone) was associated with greater reduction in ADHD-RS-IV inattentive symptoms (not total or hyperactivity/impulsive symptoms) but was only marginally significant (p=0.059; Kratochvil et al. 2005).”
BackgroundResultInfluentialGAMMON, G. D., & BROWN, T. E. (1993) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1993.3.1 · Cited by 151 · cited 2×
“Desipramine (Rapport et al. 1993; Pataki et al. 1993) or fluoxetine (Gammon and Brown 1993) can be combined with methylphenidate to treat comorbid depression.”
BackgroundKRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000222788.34229.68 · Cited by 150 · cited 1×
“Previous pooled analyses (Kratochvil et al. 2006, Wilens et al. 2006) found atomoxetine to be superior to placebo in reducing ADHD symptoms in children and adolescents.”
Weiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147 · cited 10×
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundInfluentialSpencer, T., Biederman, J., Heiligenstein, J., Wilens, T., Faries, D., Prince, J., Faraone, S. V., Rea, J., Witcher, J., & Zervas, S. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/10445460152595577 · Cited by 147 · cited 2×
“2003), two studies did not have placebo control groups (Kratochvil et al. 2001; Spencer et al. 2001), two studies compared atomoxetine and methylphenidate osmotic release oral system (OROS) (Kemner et al.”
ResultResponse to Methylphenidate in Children With ADHD and Comorbid Anxiety
DIAMOND, I. R., TANNOCK, R., & SCHACHAR, R. J. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199904000-00012 · Cited by 132 · cited 4×
“…working memory (Tannock et al. 1995) with methylphenidate treatment, although other studies found methylphenidate to be useful (Livingstone et al. 1990; Tannock et al. 1995), and others found no differential response in either comorbid status (Diamond et al. 1999; The MTA Cooperative Group 1999).”
BackgroundInfluentialBiederman, J., Spencer, T. J., Newcorn, J. H., Gao, H., Milton, D. R., Feldman, P. D., & Witte, M. M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0565-2 · Cited by 110 · cited 5×
“…finding of higher drug efficacy in girls maybe due to (1) a genuine greater efficacy in this gender (no study has compared the genders) or (2) due to a lower prevalence of comorbid ODD in this gender and ODD is associated with lower ADHD symptoms reduction (but contradicts Biederman et al. 2007).”
BackgroundResultInfluentialTodd, R. D., Sitdhiraksa, N., Reich, W., Ji, T. H.-C., Joyner, C. A., Heath, A. C., & Neuman, R. J. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00014 · Cited by 105 · cited 2×
“Children with ADHD often have academic (Faraone et al. 2001; Todd et al. 2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al.”
BackgroundFaraone, S. V., Biederman, J., Monuteaux, M. C., Doyle, A. E., & Seidman, L. J. (2001) · Journal of Attention Disorders · doi:10.1177/108705470100400404 · Cited by 105 · cited 2×
“Children with ADHD often have academic (Faraone et al. 2001; Todd et al. 2002), family (Johnston and Mash 2001) and social difficulties (Bagwell et al.”
BackgroundLong-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K., Feldman, P. D., & Levine, L. R. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.052 · Cited by 102 · cited 5×
“As the latter sites of the brain are involved in substance abuse and are not affected by atomoxetine, this drug appears an attractive alternative in children with comorbid conduct disorder at risk of substance abuse (Wilens et al. 2006).”
BackgroundInfluentialKemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005) · Advances in Therapy · doi:10.1007/bf02849870 · Cited by 99 · cited 3×
“2001), two studies compared atomoxetine and methylphenidate osmotic release oral system (OROS) (Kemner et al. 2005; Starr and Kemner 2005), one study compared atomoxetine and methylphenidate (Kratochvil et al.”
ResultRapport, M. D., Carlson, G. A., Kelly, K. L., & Pataki, C. S. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199303000-00014 · Cited by 99 · cited 1×
“Desipramine (Rapport et al. 1993; Pataki et al. 1993) or fluoxetine (Gammon and Brown 1993) can be combined with methylphenidate to treat comorbid depression.”
BackgroundSide Effects of Methylphenidate and Desipramine Alone and in Combination in Children
Pataki, C. S., Carlson, G. A., Kelly, K. L., Rapport, M. D., & Biancaniello, T. M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199309000-00028 · Cited by 92 · cited 1×
“Desipramine (Rapport et al. 1993; Pataki et al. 1993) or fluoxetine (Gammon and Brown 1993) can be combined with methylphenidate to treat comorbid depression.”
BackgroundBuitelaar, J. K., Michelson, D., Danckaerts, M., Gillberg, C., Spencer, T. J., Zuddas, A., Faries, D. E., Zhang, S., & Biederman, J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.066 · Cited by 89 · cited 11×
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundInfluentialBiederman, J., Heiligenstein, J. H., Faries, D. E., Galil, N., Dittmann, R., Emslie, G. J., Kratochvil, C. J., Laws, H. F., Schuh, K. J., & Atomoxetine ADHD Study Group (2002) · Pediatrics · doi:10.1542/peds.110.6.e75 · Cited by 87 · cited 2×
“Biederman et al. (2002) found atomoxetine to be efficacious and well tolerated in school-age girls, but there was no comparison between boys *p<0.05 and girls.”
BackgroundInfluentialPERWIEN, A. R., FARIES, D. E., KRATOCHVIL, C. J., SUMNER, C. R., KELSEY, D. K., & ALLEN, A. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200408000-00006 · Cited by 82 · cited 5×
“We also found significant improvements in QoL and functional outcome measures after atomoxetine treatment, consistent with Perwien et al. (2004).”
BackgroundMethodResultInfluentialHazell, P., Zhang, S., Wolańczyk, T., Barton, J., Johnson, M., Zuddas, A., Danckaerts, M., Ladikos, A., Benn, D., Yoran‐Hegesh, R., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0506-y · Cited by 75 · cited 5×
“2005), one study only involved comorbid ADHD+ODD subjects but did not provide enough data (Hazell et al. 2006), and all were excluded.”
BackgroundInfluentialBiederman, J., Baldessarini, R. J., WRIGHT, V., Keenan, K. E., & Faraone, S. V. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199301000-00028 · Cited by 70 · cited 1×
“Biederman et al. (1993) found desipramine to be as equally efficacious in reducing ADHD symptoms in either ADHD+/−depression comorbid status.”
BackgroundKaplan, S. L., Heiligenstein, J. H., West, S. A., Busner, J., Harder, D. F., Dittmann, R., Casat, C. D., & Wernicke, J. F. (2004) · Journal of Attention Disorders · doi:10.1177/108705470400800202 · Cited by 70 · cited 9×
“To investigate the efficacy of atomoxetine compared to placebo in reducing ADHD and ODD symptoms, we performed another set of meta-analyses (Table 3) on atomoxetine RCTs that included only comorbid ADHD+ODD subjects (Table 1).”
BackgroundInfluentialSevere liver injury after initiating therapy with atomoxetine in two children
Lim, J. D., Faught, P. R., Chalasani, N., & Molleston, J. P. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.035 · Cited by 64 · cited 1×
“Since then three children were reported to develop hepatitis after atomoxetine treatment (Lim et al. 2006; Stojanovski et al. 2007).”
BackgroundStarr, H. L., & Kemner, J. E. (2005) · PubMed · Cited by 60
An Open-Label Trial of Tomoxetine in Pediatric Attention Deficit Hyperactivity Disorder
Kratochvil, C. J., Bohac, D., Harrington, M., Baker, N., May, D., & Burke, W. J. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750284072 · Cited by 53 · cited 2×
“2003), two studies did not have placebo control groups (Kratochvil et al. 2001; Spencer et al. 2001), two studies compared atomoxetine and methylphenidate osmotic release oral system (OROS) (Kemner et al.”
ResultBiederman, J., Wigal, S. B., Spencer, T. J., McGough, J. J., & Mays, D. A. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.02.008 · Cited by 34 · cited 1×
“…attention and academic performance (Swanson, Kotkin, Atkins, M/Flynn, Pelham Scale (SKAMP) deportment and attention subscales and the number of maths problems attempted; Biederman et al. 2006), although it has to be said atomoxetine takes 6–8 weeks rather than 18 days to achieve its full effect.”
BackgroundQuintana, H., Butterbaugh, G. J., Purnell, W., & Layman, A. K. (2006) · Child Psychiatry & Human Development · doi:10.1007/s10578-006-0032-7 · Cited by 33 · cited 1×
“Fluoxetine alone reduced inattentive symptoms, but not hyperactive symptoms, in ADHD with comorbid depression (Quintana et al. 2007).”
BackgroundSoomro, G. M. (2012) · Springer eBooks · doi:10.1007/springerreference_223981 · Cited by 33
Atomoxetine-induced hepatitis in a child
Stojanovski, S. D., Casavant, M. J., Mousa, H. M., Baker, P., & Nahata, M. C. (2007) · Clinical Toxicology · doi:10.1080/15563650600795644 · Cited by 29 · cited 1×
“Since then three children were reported to develop hepatitis after atomoxetine treatment (Lim et al. 2006; Stojanovski et al. 2007).”
BackgroundGeddes, J. R., & Butler, R. (2002) · PubMed · Cited by 29
LIVINGSTON, R. L., Dykman, R. A., & Ackerman, P. T. (1992) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1992.2.115 · Cited by 25 · cited 4×
“1995) with methylphenidate treatment, although other studies found methylphenidate to be useful (Livingstone et al. 1990; Tannock et al. 1995), and others found no differential response in either comorbid status (Diamond et al.”
BackgroundInfluential2. Obsessive-compulsive Disorder
(1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000617 · Cited by 21
Soomro, G. M. (2002) · Evidence-Based Mental Health · doi:10.1136/ebmh.5.4.115 · Cited by 2
Research works printed but not linked: 3
- DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD rating scale-IV: checklists, norms, and cinical interpretations. Guilford, New York
- Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 1st edn. The Health Institute, New England Medical Center, Boston
- Tannock R, Schachar R (1992) Is ADHD with comorbid overanxious disorder different from ADHD? In: Comorbidity of ADHD: discriminating features and methodologic problems, Newcorn J (chair). Symposium conducted at the 39th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC
Cited by
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
“140 Authors of other reports suggest that more than 90% of patients will have a bene fi cial response to 1 of the psychostimulants if a range of medications from both the methylphenidate and amphetamine and/or dextroamphetamine classes”
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545
“(Cheng et al., 2007).”
Wehmeier, P. M., Schacht, A., & Barkley, R. A. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.09.009 · Cited by 628
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
“Cheng et al. [ 16 ] Meta-regression analysis of RCTs (ATX vs. Placebo) CHQ Parent 1828 ADHD NA Parent reported QoL improved with ATX treatment”
MethodInfluential
Metadata
- Authors
- Cheng, J. Y. W., Chen, R. Y. L., Ko, J. S. N., & Ng, E. M. L.
- Affiliations
- Queen Mary Hospital (CN)
- Corresponding author
- Cheng, Jackie Y. W.
- Venue
- Psychopharmacology
- Published
- 2007-06-16
- Volume
- 194
- Issue
- 2
- Pages
- 197-209
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1996091936
- Semantic Scholar
- d3e56ca1002c942102f6379b25486106538675bd
- Cited by
- 185
- References
- 64
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 7 · 2015: 11 · 2014: 13 · 2013: 21 · 2012: 18
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, children and adolescents, ADHD symptom reduction, relapse prevention, adverse events, gastrointestinal adverse effects, oppositional defiant disorder, hyperactive-impulsive subtype, inattentive subtype, quality of life, predictors of treatment response, predictors of adverse events, number needed to treat, number needed to harm, stimulant medication
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Propylamines, Quality of Life, Regression Analysis, Sex Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.